Ching-Yun Wang , Lawrence Chen , Jia-Ying Chien , Hsin-Yu Ho , Ting-Yi Lin , Shun-Ping Huang
{"title":"Tailoring UPS-to-autophagy transition to restore RGC prosperity and functionality in a rodent traumatic optic neuropathy model","authors":"Ching-Yun Wang , Lawrence Chen , Jia-Ying Chien , Hsin-Yu Ho , Ting-Yi Lin , Shun-Ping Huang","doi":"10.1016/j.exer.2025.110489","DOIUrl":null,"url":null,"abstract":"<div><div>Direct or indirect injury to the optic nerve can lead to traumatic optic neuropathy (TON), a pathological process eventually resulting in long-term vision loss. Experimentally, optic nerve crush (ONC) simulates TON by inducing retinal ganglion cell (RGC) apoptosis and vision loss. This study investigates the neuroprotective effect of a HECT domain-E3 ubiquitin ligase inhibitor, Compound 056, on retinal ganglion cells after traumatic injury. Experimental traumatic optic neuropathy (TON) was induced by mechanical compression of the rodent optic nerve. Compound 056 was administered (60 mg/kg) subcutaneously once on the same day after TON induction. Compound 056 treatment (60 mg/kg) significantly increased RGC survival and preserved visual function after TON induction. The number of TUNEL-positive cells was significantly decreased, and optic disc edema was reduced. Bulk RNA sequencing revealed that HUWE1, an E3 ubiquitin ligase, was potentially linked to the suspended autophagy and NLRP3-mediated neuroinflammation after TON induction. We demonstrated that compound 056 effectively alleviated neuroinflammation and enhanced autophagic flux at transcriptomic and protein levels. These findings suggest compound 056 may have therapeutic potential in treating TON by modulating NLRP3 inflammasome pathways and the autophagic flux within the retina and optic nerve.</div></div>","PeriodicalId":12177,"journal":{"name":"Experimental eye research","volume":"258 ","pages":"Article 110489"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental eye research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S001448352500260X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Direct or indirect injury to the optic nerve can lead to traumatic optic neuropathy (TON), a pathological process eventually resulting in long-term vision loss. Experimentally, optic nerve crush (ONC) simulates TON by inducing retinal ganglion cell (RGC) apoptosis and vision loss. This study investigates the neuroprotective effect of a HECT domain-E3 ubiquitin ligase inhibitor, Compound 056, on retinal ganglion cells after traumatic injury. Experimental traumatic optic neuropathy (TON) was induced by mechanical compression of the rodent optic nerve. Compound 056 was administered (60 mg/kg) subcutaneously once on the same day after TON induction. Compound 056 treatment (60 mg/kg) significantly increased RGC survival and preserved visual function after TON induction. The number of TUNEL-positive cells was significantly decreased, and optic disc edema was reduced. Bulk RNA sequencing revealed that HUWE1, an E3 ubiquitin ligase, was potentially linked to the suspended autophagy and NLRP3-mediated neuroinflammation after TON induction. We demonstrated that compound 056 effectively alleviated neuroinflammation and enhanced autophagic flux at transcriptomic and protein levels. These findings suggest compound 056 may have therapeutic potential in treating TON by modulating NLRP3 inflammasome pathways and the autophagic flux within the retina and optic nerve.
期刊介绍:
The primary goal of Experimental Eye Research is to publish original research papers on all aspects of experimental biology of the eye and ocular tissues that seek to define the mechanisms of normal function and/or disease. Studies of ocular tissues that encompass the disciplines of cell biology, developmental biology, genetics, molecular biology, physiology, biochemistry, biophysics, immunology or microbiology are most welcomed. Manuscripts that are purely clinical or in a surgical area of ophthalmology are not appropriate for submission to Experimental Eye Research and if received will be returned without review.